Softwr

Healthcare · head to head

Annalise.ai vs Beckman Coulter DxONE

Annalise.ai logo

Annalise.ai

Healthcare

Multi-finding chest X-ray and head CT triage AI with FDA clearance on named findings, not on the whole model

From
On request
Rated
-
Full reviewWebsite
Beckman Coulter DxONE logo

Beckman Coulter DxONE

Healthcare

Clinical laboratory middleware and informatics from a diagnostics instrument manufacturer

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Annalise.ai the United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.; Beckman Coulter DxONE the rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.
  • They diverge on capability: Annalise.ai covers Annalise Enterprise CXR, Beckman Coulter DxONE covers DxONE Command Central.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Annalise.ai and Beckman Coulter DxONE actually diverge.

Attributes where Annalise.ai and Beckman Coulter DxONE differ
AttributeAnnalise.aiBeckman Coulter DxONE
PlatformsWeb, Cloud, On-premiseWeb, Windows

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Annalise.ai

  • Annalise Enterprise CXR
  • Annalise Enterprise CTB
  • Triage and notification
  • Worklist reprioritisation
  • Localisation overlays
  • Confidence output
  • PACS-native deployment
  • On-premise or cloud inference

Only in Beckman Coulter DxONE

  • DxONE Command Central
  • DxONE Workflow Manager
  • REMISOL Advance
  • DxONE Inventory Manager
  • Autoverification rules
  • Quality control monitoring
  • LIS interfacing

What people use each for

The jobs each tool is most often brought in to do.

Annalise.ai

  • An emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnestnot Beckman Coulter DxONE
  • A teleradiology provider covering many small hospitals that needs consistent triage before a human readsnot Beckman Coulter DxONE
  • A screening programme in Europe where the broader CE marked decision support indication, rather than the narrow United States triage clearance, is what is being deployednot Beckman Coulter DxONE
  • A radiology department building an AI governance programme that wants one vendor covering both chest radiograph and head CT rather than contracting two separate algorithm suppliersnot Beckman Coulter DxONE

Beckman Coulter DxONE

  • A hospital laboratory standardising on Beckman DxC and DxI analysers that wants autoverification to release the majority of routine chemistry without technologist reviewnot Annalise.ai
  • A low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules enginenot Annalise.ai
  • A multi site laboratory network that needs identical autoverification rules applied consistently across every site, which REMISOL Advance is built fornot Annalise.ai
  • A laboratory whose LIS cannot express delta checks or repeat rules and needs that logic to live in middleware insteadnot Annalise.ai

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Annalise.ai

  • The United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.
  • Triage AI reprioritises a worklist but does not change clinical decisions on its own, so departments that do not redesign how urgent studies are picked up see no measurable improvement in time to treatment.
  • Published validation is largely reader study evidence on detection of individual findings; prospective evidence of shorter time to treatment in routine emergency care is thin.
  • The Annalise brand is being migrated under the Harrison.ai name for the critical care offering, which creates ambiguity in multi-year contracts about what product name is actually being supported.
  • A high finding count raises the alert burden, and departments report that low prevalence findings generate false positives that erode radiologist trust unless the alerting thresholds are tuned locally.

Beckman Coulter DxONE

  • The rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.
  • Pricing is bundled into analyser and reagent contracts rather than itemised, so a laboratory cannot compare the informatics cost against a standalone middleware quote and often does not know what it is paying for the software.
  • Because the software is tied to a reagent rental term, the real cost of switching middleware is the remaining years of the reagent commitment, not a software renewal, which locks the laboratory in far longer than a software contract would.
  • DxONE Workflow Manager and REMISOL Advance are different products with different rule engines rather than one product at two sizes, so a laboratory that grows out of Workflow Manager faces a migration and rule rewrite, not an upgrade.
  • Interface builds to the hospital LIS are professional services work quoted per interface, and laboratories consistently underestimate this line, particularly where the LIS is an older Sunquest or SCC installation.

Pricing, plan by plan

Annalise.ai

On request
  • Annalise Enterprise$undefined/year
    • Priced per study analysed or as an annual volume subscription
    • CXR and CTB licensed separately
    • Cleared finding set differs by market, which changes what you are buying

Beckman Coulter DxONE

On request
  • DxONE$undefined/year
    • Quoted as part of an analyser or reagent contract, not as standalone software
    • Priced against instrument fleet size and test volume
    • Multi year reagent rental agreements are the usual commercial vehicle

Which should you pick?

Choose Annalise.ai if

  • You need annalise enterprise cxr.
  • You work on Web, Cloud, On-premise.
  • You also want annalise enterprise ctb.
Annalise.ai review

Choose Beckman Coulter DxONE if

  • You need dxone command central.
  • You work on Web, Windows.
  • You also want dxone workflow manager.
Beckman Coulter DxONE review

Questions people ask

Is Annalise.ai or Beckman Coulter DxONE better?
Neither clearly leads. Annalise.ai starts at On request and Beckman Coulter DxONE at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Annalise.ai or Beckman Coulter DxONE?
Annalise.ai starts at On request and Beckman Coulter DxONE at On request.
Does Annalise.ai or Beckman Coulter DxONE run on more platforms?
Annalise.ai runs on Web, Cloud, On-premise. Beckman Coulter DxONE runs on Web, Windows.
What is Annalise.ai best used for?
Annalise.ai is most often used for an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest, a teleradiology provider covering many small hospitals that needs consistent triage before a human reads, a screening programme in europe where the broader ce marked decision support indication, rather than the narrow united states triage clearance, is what is being deployed, a radiology department building an ai governance programme that wants one vendor covering both chest radiograph and head ct rather than contracting two separate algorithm suppliers. Of those, an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest and a teleradiology provider covering many small hospitals that needs consistent triage before a human reads are not what Beckman Coulter DxONE is typically brought in for.
What can Annalise.ai do that Beckman Coulter DxONE cannot?
Annalise.ai covers Annalise Enterprise CXR, Annalise Enterprise CTB, Triage and notification, Worklist reprioritisation. Beckman Coulter DxONE covers DxONE Command Central, DxONE Workflow Manager, REMISOL Advance, DxONE Inventory Manager.

Answered from the vendors’ own pages

Annalise.ai: How many findings are FDA cleared?

Around ten across chest X-ray and head CT, for triage and notification only. The model reports far more findings than that; the rest are not cleared in the United States.

Beckman Coulter DxONE: Can I buy DxONE without buying Beckman analysers?

Not realistically. It is quoted as part of an instrument or reagent agreement and its value is in the depth of integration with Beckman platforms. A laboratory with other analysers should look at vendor neutral middleware.

Annalise.ai: Is the European position different?

Yes. CE marking under the medical device regulation covers a broader decision support indication than the United States triage and notification clearances, so the same software is a different regulatory product depending on where you deploy it.

Beckman Coulter DxONE: Is DxONE the same as REMISOL Advance?

No. REMISOL Advance is the on premises middleware for higher volume and multi site laboratories. DxONE Workflow Manager is a separate cloud product aimed at low volume laboratories. They are not the same rule engine.

Annalise.ai: Does it diagnose?

No. In the United States it is a triage and notification device: it flags studies for earlier review, and the radiologist makes the diagnosis.

Beckman Coulter DxONE: Does Beckman publish pricing?

No. Everything is quoted, and the software cost is usually folded into a cost per reportable result on a reagent contract rather than shown as a licence fee.

Annalise.ai: Is Annalise.ai becoming Harrison.ai?

The critical care offering is now marketed under the Harrison.ai name. Ask the vendor to name the contracted product explicitly before signing a multi-year deal.

Beckman Coulter DxONE: Is DxONE a regulated medical device?

The middleware components carry regulatory registrations that vary by product and region. Autoverification of diagnostic results is a regulated function, so confirm the specific clearance for the module and country before deployment.

Share

Related pages

More on Annalise.ai

More on Beckman Coulter DxONE

Keep looking

Other head to heads